Key Insights

Highlights

Success Rate

88% trial completion (above average)

Published Results

631 trials with published results (12%)

Research Maturity

2872 completed trials (54% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

7.7%

407 terminated out of 5284 trials

Success Rate

87.6%

+1.0% vs benchmark

Late-Stage Pipeline

13%

666 trials in Phase 3/4

Results Transparency

22%

631 of 2872 completed with results

Key Signals

631 with results88% success407 terminated

Data Visualizations

Phase Distribution

3,130Total
Not Applicable (1129)
Early P 1 (30)
P 1 (449)
P 2 (856)
P 3 (484)
P 4 (182)

Trial Status

Completed2,872
Unknown1,384
Terminated407
Withdrawn279
Recruiting143
Active Not Recruiting134

Trial Success Rate

87.6%

Benchmark: 86.5%

Based on 2872 completed trials

Clinical Trials (5284)

Showing 20 of 20 trials
NCT04747249Not ApplicableCompleted

Psychological Care of Oncology Patients With Post-traumatic Stress in the Context of a COVID-19

NCT07536308Phase 1RecruitingPrimary

A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults

NCT07149428Enrolling By Invitation

Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI)

NCT05384561Not ApplicableRecruiting

Olfactory Training as a Treatment for Olfactory Dysfunction Post COVID-19

NCT04991467Not ApplicableActive Not Recruiting

A Multimodal Parent-focused Intervention for Vulnerable Populations in the Bronx

NCT04794829Completed

Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination

NCT05787327Phase 2RecruitingPrimary

RCT for Yinqiaosan-Maxingganshitang in the Treatment of COVID-19

NCT05078905Active Not RecruitingPrimary

Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases

NCT05369611Enrolling By InvitationPrimary

COVID-19 Experiences in the SELF Cohort

NCT07552779Phase 1Completed

A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir

NCT07722000Not ApplicableCompletedPrimary

Different Treatment Options Used for Post Covid-19 Syndrome

NCT04924881Phase 2CompletedPrimary

Chinese Medicine for Patients With LCOVID-19 Symptoms

NCT04371432CompletedPrimary

Genetics of COVID-19 Susceptibility and Manifestations

NCT04873401Not ApplicableCompletedPrimary

Leveraging Social Networks to Increase COVID-19 Testing Uptake

NCT07215520Phase 2Active Not RecruitingPrimary

Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults

NCT07720596CompletedPrimary

Molnupiravir and COVID-19 Mortality Reduction in the Omicron Era

NCT07719166CompletedPrimary

Treatment and Outcomes in Patients With COVID-19 and Competing Acute Surgical Diseases in Moscow

NCT07709637Phase 1Active Not RecruitingPrimary

Evaluation of Safety, Tolerance, and Efficacy of Allogeneic LB-DTK-COV19 in Severe Coronavirus Disease 2019 Patients

NCT04939506Not ApplicableCompletedPrimary

COVID-19 Vaccine Education at the Point of Testing to Increase Vaccine Uptake in Vulnerable Communities in SE Louisiana

NCT05419232Not ApplicableCompleted

COVID-19 Vaccine Uptake Trial

Scroll to load more

Research Network

Activity Timeline